Your browser doesn't support javascript.
loading
FDA-approved CAR T-cell Therapy: A Decade of Progress and Challenges.
Ong, Melissa Z; Kimberly, Sharon A; Lee, Wen-Hwei; Ling, Marcus; Lee, Michael; Tan, Ke-Wei; Foo, Jhi-Biau; Yow, Hui-Yin; Sellappans, Renukha; Hamzah, Sharina.
Afiliação
  • Ong MZ; School of Pharmacy, Faculty of Health and Medical Sciences, Taylor's University, 47500, Subang Jaya, Selangor, Malaysia.
  • Kimberly SA; School of Pharmacy, Faculty of Health and Medical Sciences, Taylor's University, 47500, Subang Jaya, Selangor, Malaysia.
  • Lee WH; School of Pharmacy, Faculty of Health and Medical Sciences, Taylor's University, 47500, Subang Jaya, Selangor, Malaysia.
  • Ling M; School of Pharmacy, Faculty of Health and Medical Sciences, Taylor's University, 47500, Subang Jaya, Selangor, Malaysia.
  • Lee M; School of Pharmacy, Faculty of Health and Medical Sciences, Taylor's University, 47500, Subang Jaya, Selangor, Malaysia.
  • Tan KW; School of Pharmacy, Faculty of Health and Medical Sciences, Taylor's University, 47500, Subang Jaya, Selangor, Malaysia.
  • Foo JB; School of Pharmacy, Faculty of Health and Medical Sciences, Taylor's University, 47500, Subang Jaya, Selangor, Malaysia.
  • Yow HY; Medical Advancement for Better Quality of Life Impact Lab, Taylor's University, 47500, Subang Jaya, Selangor, Malaysia.
  • Sellappans R; Department of Pharmaceutical Life Sciences, Faculty of Pharmacy, Universiti Malaya, Kuala Lumpur, Malaysia.
  • Hamzah S; School of Pharmacy, Faculty of Health and Medical Sciences, Taylor's University, 47500, Subang Jaya, Selangor, Malaysia.
Curr Pharm Biotechnol ; 25(11): 1377-1393, 2024.
Article em En | MEDLINE | ID: mdl-39034731
ABSTRACT
CAR T-cell therapy is a promising approach for cancer treatment, utilizing a patient's own T-cells (autologous cell) or T-cells from a healthy donor (allogeneic cell) to target and destroy cancer cells. Over the last decade, significant advancements have been made in this field, including the development of novel CAR constructs, improved understanding of biology and mechanisms of action, and expanded clinical applications for treating a wider range of cancers. In this review, we provide an overview of the steps involved in the production of CAR T-cells and their mechanism of action. We also introduce different CAR T-cell therapies available, including their implementation, dosage, administration, treatment cost, efficacy, and resistance. Common side effects of CAR T-cell therapy are also discussed. The CAR T-cell products highlighted in this review are FDA-approved products, which include Kymriah® (tisagenlecleucel), Tecartus® (brexucabtagene autoleucel), Abecma® (Idecabtagene vicleucel), Breyanzi® (lisocabtagene maraleucel), and Yescarta® (axicabtagene ciloleucel). In conclusion, CAR T-cell therapy has made tremendous progress over the past decade and has the potential to revolutionize cancer treatment. This review paper provides insights into the progress, challenges, and future directions of CAR T-cell therapy, offering valuable information for researchers, clinicians, and patients.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: United States Food and Drug Administration / Imunoterapia Adotiva / Receptores de Antígenos Quiméricos / Neoplasias Limite: Animals / Humans País/Região como assunto: America do norte Idioma: En Revista: Curr Pharm Biotechnol Assunto da revista: BIOTECNOLOGIA / FARMACOLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Malásia

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: United States Food and Drug Administration / Imunoterapia Adotiva / Receptores de Antígenos Quiméricos / Neoplasias Limite: Animals / Humans País/Região como assunto: America do norte Idioma: En Revista: Curr Pharm Biotechnol Assunto da revista: BIOTECNOLOGIA / FARMACOLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Malásia